Featured Jobs
|
Strategic Retirement Plan Consultant Retirement Plan Consultants
|
|
Relationship Manager for Defined Contributions KP Daybright Financial
|
|
DWC - The 401(k) Experts
|
|
MAP Retirement
|
|
Plan Administrator, Defined Benefit & Cash Balance The Pension Source
|
|
Sentinel Group
|
|
Defined Benefit Plan Consultant/Actuarial Analyst Sentinel Group
|
|
MAP Retirement
|
|
Retirement Plan Onboarding Specialist Compass
|
|
BPAS
|
|
Pattison Pension
|
|
Regional Vice President, Sales MAP Retirement
|
|
Retirement Relationship Manager MAP Retirement
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
GAO Report: Brand-Name Prescription Drug Pricing -- Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases
U.S. Government Accountability Office [GAO] 
Jan. 11, 2010
40 pages. "GAO was asked to examine extraordinary price increases for brand-name prescription drugs. Specifically, GAO examined the: [1] frequency of extraordinary price increases for brand-name prescription drugs from 2000 to 2008, [2] characteristics of the brand-name prescription drugs that had extraordinary price increases, and [3] factors that contributed to the extraordinary price increases experienced by these brand-name prescription drugs." [GAO-10-201, published Dec. 22, 2009, released Jan. 11, 2010]
|
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |